Finally, the heterogeneity of the tumor microenvironment (TME) may influence response to MerTK/Axl inhibition, emphasizing the need for rational combination strategies and robust pharmacodynamic markers in future clinical development (136–138). Here, MERTK is linked to neoplasm.